HMGA2 Antibody

1. we demonstrate that HMGA2 is correlated with GC VM formation and that positivity for both HMGA2 and VM predicts a worse clinical outcome for GC patients. HMGA2 can directly target Twist1 and promote the expression of Twist1 and VE-cadherin. PMID: 28533522
2. Rearrangement of PLAG1 and HMGA2 and expression of the corresponding proteins are frequent and specific findings in lacrimal gland pleomorphic adenoma (PA) and ca-ex-PA. PMID: 29437290
3. we conclude that the fragment HMGA2-sh-3p20 from HMGA2 mRNA 3'UTR promotes the growth of hepatoma cells by upregulating HMGA2. PMID: 28522832
4. HMGA2-EGFR constitutively induced a higher level of phosphorylated STAT5B than EGFRvIII. PMID: 29193056
5. we aimed in this study to examine these common functional pathways in uterine leiomyomas (ULM)with different driver mutations. We collected ULM with MED12, HMGA2, and FH mutations and examined the selected markers by immunohistochemistry. PMID: 29790226
6. Here, we observed that overexpression of HMGA2 mRNA in tumors measured by quantitative PCR and compared to myometrium is a common phenomenon in fibroids and is frequently associated with MED12 mutations. In addition, the common clonal origin of tumors overexpressing HMGA2 mRNA and its expression in few myometrial tissue points to HMGA2 up-regulation as an early event in leiomyoma tumorigenesis. PMID: 30017537
7. HMGA2 overexpression appears to be a strong feature of larynx carcinoma, supporting its detection as a valid tool for the diagnosis of these malignancies. PMID: 29266325
8. These results suggest that miR599 may serve tumour suppressive roles in cell renal cell carcinoma (ccRCC) by directly targeting HMGA2, indicating that miR599 may have potential as a treatment for patients with ccRCC. PMID: 29568870
9. HMGA2 was highly expressed in NSCLC tissues and cells and its overexpression was correlated with low-grade differentiation, lymph node metastasis, advanced clinical stage and poor survival time of NSCLC, which suggested that it could serve as a potential molecular marker and prognostic index for NSCLC. PMID: 29278873
10. miR-539 acted as a tumor suppressor in RCC cells by suppressing cell proliferation and inducing cell apoptosis, and this suppression may be due, at least in part, to the modulation of HMGA2 through the AKT signaling pathway. PMID: 29436648
11. The data suggest that HMGA2 is regulated in Oesophageal adenocarcinoma (EAC) primarily through non-chromosomal-level alterations that lead to increased HMGA2 expression. HMGA2-positive EAC correlates with adverse pathological features and worse patient outcomes. PMID: 28710822
12. Study found that HMGA2 was highly expressed in five renal cell carcinoma cell lines compared with that in the normal renal tubular epithelial HK2 cell line. Further results demonstrated that HMGA2 facilitated a metastatic phenotype and the EMT process in renal cell carcinoma cells in vitro through a TGF-beta-dependent pathway. PMID: 29138866
13. miR-194 is as important as HMGA2, and both coordinately regulate the oncogenesis of colorectal cancer. PMID: 29109785
14. HMGA2 expression is a highly specific (96.2%), but low-sensitivity (29.8%), marker for pleomorphic adenoma (PA) and carcinoma ex-pleomorphic adenoma (CA ex-PA) when compared with histological mimics, and is frequently associated with rearrangement of the HMGA2 locus. PMID: 28463429
15. NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer PMID: 28720546
16. In ACTH-secreting pituitary tumors, HMGA2 was expressed in 4 of 28 nonrecurrent tumors and 3 of 27 recurrent tumors. It was expressed predominantly in the nucleus and moderately in the cytoplasm of the tumor cells. There was no significant difference between HMGA2 expression between the nonrecurrent group and the recurrent group. PMID: 29432944
17. Results identified de novo heterozygous 7.3kb deletion on chromosome 12q14.3 including exon 1 and 2 of HMGA2 in a patient with Silver-Russell syndrome (SRS). The review of available data along with these results provide evidence that HMGA2 is another causative gene for SRS. PMID: 29655892
18. This study demonstrated that the transactivation of FOXL2 driven by interactions between HMGA2 and pRb might exert critical effects on the metastases and EMT of chemoresistant gastric cancer. Blocking the HMGA2-FOXL2-ITGA2 pathway could serve as a new strategy for gastric cancer treatment. PMID: 28119367
19. miR-219 functions as a tumor suppressor and may be important in inhibiting the growth and metastasis of Non-small cell lung cancer cells via directly targeting HMGA2. PMID: 28714014
20. Results showed that HMGA2 was upregulated and associated with lung adenocarcinoma (LAC) prognosis. HMGA2, regulated by miR-195, could directly regulate cell motility and proliferation in LAC cells. PMID: 28752530
21. Depletion of HMGA2 in GICs resulted in compromised self-renewal and tumorigenic capability, as well as undermined mesenchymal or pericyte differentiation. PMID: 27259253
22. HMGA2 might play an important role in the progression of colorectal carcinoma and might be a potential therapeutic target for trigger apoptosis and cell cycle arrest in colorectal carcinoma. PMID: 27629422
23. these results show that squamous cell carcinomas of the vulva presents a characteristic molecular pattern with FHIT being downregulated whereas HMGA2 is upregulated PMID: 27835588
24. HMGA2 expression is associated with a risk increase for adverse outcomes in patients with HNSCC of the larynx and oral cavity. PMID: 27742669
25. insights into how HMGA2 interacts with stalled RFs and the function of the process PMID: 29262356
26. HRAS mutations were more common in epithelial-myoepithelial carcinomas (EMCAs) with intact PLAG1 and HMGA2. Most EMCAs arose ex pleomorphic adenoma (PA)and the genetic profile of EMCA varies with the absence or presence of preexisting PA and its cytogenetic signature. Progression to higher grade EMCA with intact PLAG1 and HMGA2 correlates with the presence of TP53, FBXW7 mutations, or SMARCB1 deletion. PMID: 29135520
27. our data demonstrate a unique and novel role of HMGA2 in telomere protection and promoting telomere stability in cancer cells PMID: 26799419
28. Results sugges that HMGA2 overexpression is involved in esophageal Squamous Cell Carcinoma progression PMID: 27027341
29. Data show that KRAS, MTA1 and HMGA2 are direct targets of miR-543. PMID: 26968810
30. HMGA2 expression level associates with key clinic-pathologic features and could be an effective biomarker to predict the prognosis of ESCC. PMID: 27119517
31. results suggested that overexpression of miR-125b-5p inhibited cell proliferation, migration and invasion partially by down-regulating HMGA2 in ESCC PMID: 28968424
32. This study identified HMGA2 as important downsteam target of let-7a in Pancreatic Cancer Cells and overexpression of HMGA2 restores cell proliferation, metastasis and chemosensitivity of gemcitabine inhibited by let-7a. PMID: 28954272
33. Let-7b might function as a tumor suppressor in papillary thyroid carcinoma by suppressing the expression of high-mobility group A2, and therefore might provide a promising therapeutic target for patients with papillary thyroid carcinoma. PMID: 29025376
34. Our findings demonstrated that HMGA2 may promote malignant transformation of TSCC through EMT process and may be an independent prognosis biomarker for TSCC. PMID: 27809392
35. Study provides the first evidence that miR-4500 functions as a novel tumor suppressor in the miR-4500/HMGA2 axis in colorectal carcinogenesis. PMID: 27686621
36. Our study shows that genomic imbalances are involved in miR-30c and let-7a deregulation. One can reasonably assume that dysregulation of these miRNAs is a cause leading to HMGA2 upregulation in ovarian tumors. PMID: 28423547
37. Expression levels of HULC are positively correlated with those of HMGA2 in clinical hepatocellular carcinoma tissues. Data suggest that HULC up-regulates expression of HMGA2 in hepatocytes and enhances hepatocarcinogenesis; microRNA-186 inhibits HMGA2 expression by targeting the 3prime-untranslated region of HMGA2 mRNA. (HULC = HULC long non-coding RNA HULC; HMGA2 = high mobility group AT-hook 2) PMID: 28765279
38. results show that HMGA2 expression is associated with highly proliferating MSCs, is tightly regulated by FGF-2, and is involved in both proliferation and adipogenesis of Mesenchymal stem cells. PMID: 26888666
39. Intraductal papillary mucinous neoplasm cyst fluid HMGA2 level was higher in invasive pancreatic cancer and high grade dysplasia compared to moderate and low grade dysplasia. PMID: 26408423
40. our findings suggest that X-linked inhibitor of apoptosis protein 3'-untranslated region serves as a competitive endogenous RNA for HMGA2 to activate hepatocellular carcinoma progression by arresting endogenous let-7a-5p. PMID: 28691642
41. angiotensin II type 2 receptor-interacting protein 3a presents potential in suppressing the proliferation and aggressiveness of ovarian carcinoma cells through the high mobility group AT-hook 2-mediated extracellular signal-regulated kinase/epithelial-to-mesenchymal transition signal pathway. PMID: 28651497
42. HMGA2 promotes stemness and tumorigenicity in glioblastoma cell lines. PMID: 27102002
43. in a subset of myeloproliferative neoplasm patients, the let-7-HMGA2 axis plays a prominent role in the pathogenesis of the disease that leads to unique clinical phenotypes. PMID: 28057739
44. The expression of miR-33b decreases and HMGA2 increases in the esophageal squamous cell carcinoma. PMID: 27609581
45. HIT000218960 might acts as a tumor promoter through regulating the expression of HMGA2. PMID: 27929737
46. our data suggest that expression of HMGA2, a downstream target of let-7 miRNAs, causes moderately increased gamma-globin gene and protein expression in adult human erythroblasts. PMID: 27861570
47. HMGA2 potentiates the clinically important topoisomerase I inhibitor irinotecan/SN-38 in trapping the enzyme in covalent DNA-complexes, thereby attenuating transcription. PMID: 27587582
48. knockdown of HMGI-C led to the significant induction of apoptosis via mitochondrial pathway by inducing miR34a and cell cycle arrest in MDA-MB-468 cells in vitro. PMID: 27245202
49. miR-495 was significantly downregulated in cancer tissue and cell lines (p<0.05). Its overexpression inhibited cell migration and invasion, elevated CDH1, and inhibited VIM and ACTA2 levels in BGC-823 and HGC-27 cells. miR-495 directly inhibited HMGA2, which was upregulated in gastric cancer tissue, and promoted cell migration and invasion, inhibited CDH1, and elevated VIM and ACTA2. PMID: 28159956
50. MiR-107 suppresses the proliferation of hepatoma cells by targeting HMGA2 mRNA. Our finding provides new insights into the mechanism of hepatocarcinogenesis. PMID: 27773820

Show More

Hide All

HGNC: 5009

OMIM: 150699

KEGG: hsa:8091

STRING: 9606.ENSP00000384026

UniGene: Hs.505924